Clinical Trials Logo

Extra-adrenal Paraganglioma clinical trials

View clinical trials related to Extra-adrenal Paraganglioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01340794 Terminated - Paraganglioma Clinical Trials

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Start date: May 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced or progressive malignant pheochromocytoma or paraganglioma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT01152827 Completed - Pheochromocytoma Clinical Trials

RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid

PheoCarcRAD001
Start date: July 2008
Phase: Phase 2
Study type: Interventional

- According to Martin F et al, AKT is highly phosphorylated in phenochromocytoma but not in benign adrenocortical tumors. - In nonfunctioning carcinoid, the PI3K/AKT/mTOR pathway is activated. - Although mTOR is clearly an attractive therapeutic target in tumor, no clinical study on mTOR inhibition by RAD001 have been conducted in pheochromocytoma or extra-adrenal paraganglioma or non-functioning carcinoid. - So we design this phase II study of RAD001 in pheochromocytoma or extra-adrenal paraganglioma or non-functioning carcinoid to evaluate the efficacy of RAD001 in this orphan disease.

NCT ID: NCT01076530 Completed - Clinical trials for Recurrent Childhood Ependymoma

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Start date: February 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug.